MARKET

AIKI

AIKI

AIkido Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.5800
+0.0399
+7.39%
After Hours: 0.5380 -0.042 -7.24% 19:06 10/28 EDT
OPEN
0.5600
PREV CLOSE
0.5401
HIGH
0.6196
LOW
0.5100
VOLUME
3.71M
TURNOVER
--
52 WEEK HIGH
5.52
52 WEEK LOW
0.4748
MARKET CAP
20.25M
P/E (TTM)
-0.2799
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
AIkido Pharma Inc. Provides Update on Its Next-Generation Chemotherapeutic Treatment DHA-dFdC
AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided an update on its preclinical work on its next-generation chemotherapeutic, DHA-dFdC, and the solid lipid nanoparticle (SLN) drug delivery system to treat pancreatic cancer, which the Company has licensed from the University of Texas at Austin.
PR Newswire · 10h ago
AIkido Pharma Provides Update On Next-Generation Chemotherapeutic Treatment DHA-dFdC
AIkido Pharma Inc. Provides Update on Its Next-Generation Chemotherapeutic Treatment DHA-dFdC NEW YORK, Oct. 28, 2020 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ:AIKI) ("AIkido" or the
Benzinga · 11h ago
Alkido Pharma Announces Update On Co's Use Of Artificial Intelligence
AIkido Pharma Announces Update On Its Use Of Artificial Intelligence NEW YORK, Sept. 18, 2020 /PRNewswire/ --AIkido Pharma Inc. (NASDAQ:AIKI) today announced that its work with research partner, Cogia BioTech
Benzinga · 09/18 14:01
AIkido Pharma Inc. Announces Participation at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14-16, 2020 (Virtual Conference)
AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced it will be featured as a presenting company at the H.C. Wainwright 22nd Annual Global Investment Conference. The conference is being held on September 14-16, 2020 virtually.
PR Newswire · 09/11 14:00
AIkido Pharma Announces Peer-Reviewed Publication of Positive Results from Study of Antiviral Compounds Licensed from University of Maryland, Baltimore
AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced the publication of positive results from a study of antiviral activity of FDA approved drugs in a peer-reviewed article in the Journal of Virology. The publication cites that 17 of the 20 FDA-approved drugs
PR Newswire · 09/11 14:00
AIkido Pharma Highlights Peer-Reviewed Publication Of Results From Study Of Antiviral Compounds Licensed From University Of Maryland
AIkido Pharma Inc. (NASDAQ:AIKI) ("AIkido" or the "Company") today announced the publication of positive results from a study of antiviral activity of FDA approved drugs in a peer-reviewed article in
Benzinga · 09/11 13:06
LD Micro - 360 Companies Set to Present this Week
ACCESSWIRE · 08/31 22:00
AIkido Pharma Sponsors Survival Study of University of Kentucky Anticancer Drug G4-1 in Exchange for Exclusive Option to License
AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that it will provide funding for a 30-day survival study in mice in collaboration with University of Kentucky related to the anticancer drug designated G4-1, a novel proteasome inhibitor. In exchange, Aikido
PR Newswire · 08/18 14:00
More
Forecast
EPSBVPSCFPS
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AIKI. Analyze the recent business situations of AIkido Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Institutional Holdings
Institutions: 26
Institutional Holdings: 655.99K
% Owned: 1.88%
Shares Outstanding: 34.92M
TypeInstitutionsShares
Increased
0
0
New
17
321.64K
Decreased
3
4.74K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.24%
Pharmaceuticals & Medical Research
-2.11%
Key Executives
Chairman/Director
Robert Vander Zanden
Chief Executive Officer/Chief Financial Officer/Chief Accounting Officer/Director
Anthony Hayes
Director
Gregory Blattner
Director
Robert Dudley
Director
Paul LeMire
Independent Director
Tim Ledwick
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About AIKI
Aikido Pharma Inc., formerly Spherix Incorporated, is a biotechnology company. The Company is focused on developing a diverse portfolio of small-molecule anti-cancer therapeutics. Its diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In addition, the Company is constantly seeking to grow its pipeline to treat its unmet medical needs in oncology.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Aikido Pharma Inc stock information, including NASDAQ:AIKI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AIKI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AIKI stock methods without spending real money on the virtual paper trading platform.